

Notice under Section 708A(5)(e) of the Corporations Act

29 October 2024: Orthocell Limited ASX: OCC, “Orthocell” or “the Company”) advises that it has today issued 271,134 fully paid ordinary shares (**Shares**) following the cashless exercise of 630,000 \$0.50 26 October 2024 options and the exercise of 100,000 \$0.36 19 April 2027 options.

The Company gives notice under section 708(5)(e) of the Corporations Act 2001 (Cth) (“**Act**”) that:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) the notice is being given under section 708A(5)(e) of the Act;
- (c) as at the date of this notice the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and
 - (ii) sections 674 and 674A of the Act; and
- (d) as at the date of this notice, there is no information that is ‘excluded information’ within the meanings of sections 708(A)(7) and 708A(8) of the Act that is required to be set out in this notice.

Release authorised by the Board of Orthocell Limited.

For more information, please contact:

General & Investor enquiries

Paul Anderson

Orthocell Limited

Managing Director

P: +61 8 9360 2888

E: paul.anderson@orthocell.com.au

Media enquiries

Haley Chartres

HACK Director

P: +61 423 139 163

E: haley@hck.digital

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell’s portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in US FDA (510k), Australia (ARTG), New Zealand (WAND), UK (UKCA Mark) and Europe (CE Mark) and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently received approval and reimbursement in Australia and is distributed exclusively by Device Technologies in the Australian market. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company’s other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

